{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:09:26Z","timestamp":1790392166167,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EUN Egyptian Universities Network"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biotechnol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recently, natural and synthetic nitrogenous heterocyclic antivirals topped the scene as first choices for the treatment of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and their accompanying disease, the coronavirus disease 2019 (COVID-19). Meanwhile, the mysterious evolution of a new strain of SARS-CoV-2, the Omicron variant and its sublineages, caused a new defiance in the continual COVID-19 battle. Hitting the two principal coronaviral-2 multiplication enzymes RNA-dependent RNA polymerase (RdRp) and 3\u2032-to-5\u2032 exoribonuclease (ExoN) synchronously using the same ligand is a highly effective novel dual pathway to hinder SARS-CoV-2 reproduction and stop COVID-19 progression irrespective of the SARS-CoV-2 variant type since RdRps and ExoNs are widely conserved among all SARS-CoV-2 strains. Herein, the present computational\/biological study screened our previous small libraries of nitrogenous heterocyclic compounds, searching for the most ideal drug candidates predictably able to efficiently act through this double approach. Theoretical filtration gave rise to three promising antioxidant nitrogenous heterocyclic compounds of the 1,3,4-thiadiazole type, which are CoViTris2022, Taroxaz-26, and ChloViD2022. Further experimental evaluation proved for the first time, utilizing the in vitro anti-RdRp\/ExoN and anti-SARS-CoV-2 bioassays, that ChloViD2022, CoViTris2022, and Taroxaz-26 could effectively inhibit the replication of the new virulent strains of SARS-CoV-2 with extremely minute in vitro anti-RdRp and anti-SARS-CoV-2 EC<jats:sub>50<\/jats:sub> values of 0.17 and 0.41\u00a0\u03bcM for ChloViD2022, 0.21 and 0.69\u00a0\u03bcM for CoViTris2022, and 0.23 and 0.73\u00a0\u03bcM for Taroxaz-26, respectively, transcending the anti-COVID-19 drug molnupiravir. The preliminary in silico outcomes greatly supported these biochemical results, proposing that the three molecules potently strike the key catalytic pockets of the SARS-CoV-2 (Omicron variant) RdRp\u2019s and ExoN\u2019s vital active sites. Moreover, the idealistic pharmacophoric hallmarks of CoViTris2022, Taroxaz-26, and ChloViD2022 molecules relatively make them typical dual-action inhibitors of SARS-CoV-2 replication and proofreading, with their highly flexible structures open for various kinds of chemical derivatization. To cut it short, the present pivotal findings of this comprehensive work disclosed the promising repositioning potentials of the three 2-aminothiadiazoles, CoViTris2022, Taroxaz-26, and ChloViD2022, to successfully interfere with the crucial biological interactions of the coronaviral-2 polymerase\/exoribonuclease with the four principal RNA nucleotides, and, as a result, cure COVID-19 infection, encouraging us to rapidly start the three drugs\u2019 broad preclinical\/clinical anti-COVID-19 evaluations.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>\n                <jats:p>Dual SARS-CoV-2 polymerase (RdRp) and exoribonuclease (ExoN) inhibition via nucleoside mimicry is a very effective novel approach for COVID-19 infection therapy. Hydroxylated nitrogenous heterocyclic compounds are currently considered first choices in COVID-19 therapy. Extensive computational investigations disclosed three synthetic 5-substituted-2-amino-1,3,4-thiadiazoles, CoViTris2022, Taroxaz-26, and ChloViD2022, with ideal anti-RdRp\/ExoN features. ChloViD2022 was ranked the top among the three NAs, with biochemical anti-RdRp EC<jats:sub>50<\/jats:sub> value of 0.17\u00a0\u03bcM. ChloViD2022 accordingly displayed excellent anti-SARS-CoV-2 EC<jats:sub>50<\/jats:sub> value of 0.41\u00a0\u03bcM against the Omicron variant.<\/jats:p>","DOI":"10.1007\/s12033-022-00551-8","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T03:49:25Z","timestamp":1674532165000},"page":"592-611","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Potent Dual Polymerase\/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico\/In Vitro Repositioning Research Study"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-114X","authenticated-orcid":false,"given":"Amgad M.","family":"Rabie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3981-201X","authenticated-orcid":false,"given":"Wafa A.","family":"Eltayb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"551_CR1","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12967-020-02476-9","volume":"18","author":"VC Chitalia","year":"2020","unstructured":"Chitalia, V. C., & Munawar, A. H. (2020). A painful lesson from the COVID-19 pandemic: The need for broad-spectrum, host-directed antivirals. Journal of Translational Medicine, 18, 390. https:\/\/doi.org\/10.1186\/s12967-020-02476-9","journal-title":"Journal of Translational Medicine"},{"key":"551_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","volume":"6","author":"X Wang","year":"2020","unstructured":"Wang, X., Cao, R., Zhang, H., Liu, J., Xu, M., Hu, H., Li, Y., Zhao, L., Li, W., Sun, X., Yang, X., Shi, Z., Deng, F., Hu, Z., Zhong, W., & Wang, M. (2020). The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discovery, 6, 28. https:\/\/doi.org\/10.1038\/s41421-020-0169-8","journal-title":"Cell Discovery"},{"key":"551_CR3","doi-asserted-by":"publisher","first-page":"174233","DOI":"10.1016\/j.ejphar.2021.174233","volume":"906","author":"H Kaur","year":"2021","unstructured":"Kaur, H., Sarma, P., Bhattacharyya, A., Sharma, S., Chhimpa, N., Prajapat, M., Prakash, A., Kumar, S., Singh, A., Singh, R., Avti, P., Thota, P., & Medhi, B. (2021). Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors \u201cleflunomide\u201d and \u201cteriflunomide\u201d in Covid-19: A narrative review. European Journal of Pharmacology, 906, 174233. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174233","journal-title":"European Journal of Pharmacology"},{"key":"551_CR4","doi-asserted-by":"publisher","first-page":"100055","DOI":"10.1016\/j.crphar.2021.100055","volume":"2","author":"AM Rabie","year":"2021","unstructured":"Rabie, A. M. (2021). Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19. Current Research in Pharmacology and Drug Discovery, 2, 100055. https:\/\/doi.org\/10.1016\/j.crphar.2021.100055","journal-title":"Current Research in Pharmacology and Drug Discovery"},{"key":"551_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107831","volume":"98","author":"AM Rabie","year":"2021","unstructured":"Rabie, A. M. (2021). Cyanorona-20: The first potent anti-SARS-CoV-2 agent. International Immunopharmacology, 98, 107831. https:\/\/doi.org\/10.1016\/j.intimp.2021.107831","journal-title":"International Immunopharmacology"},{"key":"551_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12879-021-05773-w","volume":"21","author":"A Ip","year":"2021","unstructured":"Ip, A., Ahn, J., Zhou, Y., Goy, A. H., Hansen, E., Pecora, A. L., Sinclaire, B. A., Bednarz, U., Marafelias, M., Sawczuk, I. S., Underwood, J. P., III, Walker, D. M., Prasad, R., Sweeney, R. L., Ponce, M. G., La Capra, S., Cunningham, F. J., Calise, A. G., Pulver, B. L., \u2026 Goldberg, S. L. (2021). Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study. BMC Infectious Diseases, 21, 72. https:\/\/doi.org\/10.1186\/s12879-021-05773-w","journal-title":"BMC Infectious Diseases"},{"key":"551_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","volume":"9","author":"J-C Tardif","year":"2021","unstructured":"Tardif, J.-C., Bouabdallaoui, N., L\u2019Allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., Lopez-Sendon, J., Da Luz, P., Verret, L., Audet, S., Dupuis, J., Denault, A., Pelletier, M., Tessier, P. A., Samson, S., Fortin, D., Tardif, J.-D., Busseuil, D., Goulet, E., et al. (2021). Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respiratory Medicine, 9, 924\u2013932. https:\/\/doi.org\/10.1016\/S2213-2600(21)00222-8","journal-title":"Lancet Respiratory Medicine"},{"key":"551_CR8","doi-asserted-by":"publisher","first-page":"n2713","DOI":"10.1136\/bmj.n2713","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase, E. (2021). Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ, 375, n2713. https:\/\/doi.org\/10.1136\/bmj.n2713","journal-title":"BMJ"},{"key":"551_CR9","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.3390\/molecules26195795","volume":"26","author":"M Imran","year":"2021","unstructured":"Imran, M., Kumar Arora, M., Asdaq, S. M. B., Khan, S. A., Alaqel, S. I., Alshammari, M. K., Alshehri, M. M., Alshrari, A. S., Mateq Ali, A., Al-shammeri, A. M., Alhazmi, B. D., Harshan, A. A., Alam, M. T., & Abida (2021). Discovery, development, and patent trends on molnupiravir: A prospective oral treatment for COVID-19. Molecules, 26, 5795. https:\/\/doi.org\/10.3390\/molecules26195795","journal-title":"Molecules"},{"key":"551_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.2174\/1389450121999201202110303","volume":"22","author":"DS Moirangthem","year":"2021","unstructured":"Moirangthem, D. S., & Surbala, L. (2021). Remdesivir (GS-5734) in COVID-19 therapy: The fourth chance. Current Drug Targets, 22, 1346\u20131356. https:\/\/doi.org\/10.2174\/1389450121999201202110303","journal-title":"Current Drug Targets"},{"key":"551_CR11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","volume":"11","author":"VC Yan","year":"2020","unstructured":"Yan, V. C., & Muller, F. L. (2020). Advantages of the parent nucleoside GS-441524 over remdesivir for Covid-19 treatment. ACS Medicinal Chemistry Letters, 11, 1361\u20131366. https:\/\/doi.org\/10.1021\/acsmedchemlett.0c00316","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"551_CR12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3390\/pharmaceutics13091400","volume":"13","author":"L Brunotte","year":"2021","unstructured":"Brunotte, L., Zheng, S., Mecate-Zambrano, A., Tang, J., Ludwig, S., Rescher, U., & Schloer, S. (2021). Combination therapy with fluoxetine and the nucleoside analog GS-441524 exerts synergistic antiviral effects against different SARS-CoV-2 variants in vitro. Pharmaceutics, 13, 1400. https:\/\/doi.org\/10.3390\/pharmaceutics13091400","journal-title":"Pharmaceutics"},{"key":"551_CR13","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1021\/acsomega.1c05998","volume":"7","author":"AM Rabie","year":"2022","unstructured":"Rabie, A. M. (2022). Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega, 7, 2960\u20132969. https:\/\/doi.org\/10.1021\/acsomega.1c05998","journal-title":"ACS Omega"},{"key":"551_CR14","doi-asserted-by":"publisher","first-page":"21385","DOI":"10.1021\/acsomega.1c07095","volume":"7","author":"AM Rabie","year":"2022","unstructured":"Rabie, A. M. (2022). Efficacious preclinical repurposing of the nucleoside analogue Didanosine against COVID-19 polymerase and exonuclease. ACS Omega, 7, 21385\u201321396. https:\/\/doi.org\/10.1021\/acsomega.1c07095","journal-title":"ACS Omega"},{"key":"551_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., Shen, C., Li, X., Peng, L., Huang, D., Zhang, J., Zhang, S., Wang, F., Liu, J., Chen, L., et al. (2020). Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering, 6, 1192\u20131198. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007","journal-title":"Engineering"},{"key":"551_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1039\/D0NJ03708G","volume":"45","author":"AM Rabie","year":"2021","unstructured":"Rabie, A. M. (2021). Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): Successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs. New Journal of Chemistry, 45, 761\u2013771. https:\/\/doi.org\/10.1039\/D0NJ03708G","journal-title":"New Journal of Chemistry"},{"key":"551_CR17","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s11030-020-10169-0","volume":"25","author":"AM Rabie","year":"2021","unstructured":"Rabie, A. M. (2021). CoViTris2020 and ChloViD2020: A striking new hope in COVID-19 therapy. Molecular Diversity, 25, 1839\u20131854. https:\/\/doi.org\/10.1007\/s11030-020-10169-0","journal-title":"Molecular Diversity"},{"key":"551_CR18","doi-asserted-by":"publisher","first-page":"109480","DOI":"10.1016\/j.cbi.2021.109480","volume":"343","author":"AM Rabie","year":"2021","unstructured":"Rabie, A. M. (2021). Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles. Chemico-Biological Interactions, 343, 109480. https:\/\/doi.org\/10.1016\/j.cbi.2021.109480","journal-title":"Chemico-Biological Interactions"},{"key":"551_CR19","doi-asserted-by":"publisher","first-page":"131106","DOI":"10.1016\/j.molstruc.2021.131106","volume":"1246","author":"AM Rabie","year":"2021","unstructured":"Rabie, A. M. (2021). Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012\/01 strain. Journal of Molecular Structure, 1246, 131106. https:\/\/doi.org\/10.1016\/j.molstruc.2021.131106","journal-title":"Journal of Molecular Structure"},{"key":"551_CR20","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","volume":"19","author":"M Chien","year":"2020","unstructured":"Chien, M., Anderson, T. K., Jockusch, S., Tao, C., Li, X., Kumar, S., Russo, J. J., Kirchdoerfer, R. N., & Ju, J. (2020). Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. Journal of Proteome Research, 19, 4690\u20134697. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00392","journal-title":"Journal of Proteome Research"},{"key":"551_CR21","unstructured":"Retrieved Mar 28, 2022 from https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants"},{"key":"551_CR22","unstructured":"Retrieved Mar 28, 2022 from https:\/\/www.washingtonpost.com\/health\/2021\/12\/16\/omicron-variant-mutations-covid"},{"key":"551_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7537\/marsrsj100718.04","volume":"10","author":"AM Rabie","year":"2018","unstructured":"Rabie, A. M., Tantawy, A. S., & Badr, S. M. I. (2018). Design, synthesis, and biological evaluation of new 5-substituted-1,3,4-thiadiazole-2-thiols as potent antioxidants. Researcher, 10, 21\u201343. https:\/\/doi.org\/10.7537\/marsrsj100718.04","journal-title":"Researcher"},{"key":"551_CR24","doi-asserted-by":"publisher","first-page":"647693","DOI":"10.3389\/fmicb.2021.647693","volume":"12","author":"S Khater","year":"2021","unstructured":"Khater, S., Kumar, P., Dasgupta, N., Das, G., Ray, S., & Prakash, A. (2021). Combining SARS-CoV-2 proofreading exonuclease and RNA-dependent RNA polymerase inhibitors as a strategy to combat COVID-19: A high-throughput in silico screening. Frontiers in Microbiology, 12, 647693. https:\/\/doi.org\/10.3389\/fmicb.2021.647693","journal-title":"Frontiers in Microbiology"},{"key":"551_CR25","doi-asserted-by":"publisher","first-page":"105254","DOI":"10.1016\/j.antiviral.2022.105254","volume":"198","author":"J Zhao","year":"2022","unstructured":"Zhao, J., Liu, Q., Yi, D., Li, Q., Guo, S., Ma, L., Zhang, Y., Dong, D., Guo, F., Liu, Z., Wei, T., Li, X., & Cen, S. (2022). 5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis. Antiviral Research, 198, 105254. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105254","journal-title":"Antiviral Research"},{"key":"551_CR26","doi-asserted-by":"publisher","first-page":"105078","DOI":"10.1016\/j.antiviral.2021.105078","volume":"190","author":"J Zhao","year":"2021","unstructured":"Zhao, J., Guo, S., Yi, D., Li, Q., Ma, L., Zhang, Y., Wang, J., Li, X., Guo, F., Lin, R., Liang, C., Liu, Z., & Cen, S. (2021). A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Research, 190, 105078. https:\/\/doi.org\/10.1016\/j.antiviral.2021.105078","journal-title":"Antiviral Research"},{"key":"551_CR27","doi-asserted-by":"publisher","first-page":"113233","DOI":"10.1016\/j.ejmech.2021.113233","volume":"214","author":"X Lin","year":"2021","unstructured":"Lin, X., Liang, C., Zou, L., Yin, Y., Wang, J., Chen, D., & Lan, W. (2021). Advance of structural modification of nucleosides scaffold. European Journal of Medicinal Chemistry, 214, 113233. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113233","journal-title":"European Journal of Medicinal Chemistry"},{"key":"551_CR28","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.3390\/molecules26206151","volume":"26","author":"IH Eissa","year":"2021","unstructured":"Eissa, I. H., Khalifa, M. M., Elkaeed, E. B., Hafez, E. E., Alsfouk, A. A., & Metwaly, A. M. (2021). In silico exploration of potential natural inhibitors against SARS-Cov-2 nsp10. Molecules, 26, 6151. https:\/\/doi.org\/10.3390\/molecules26206151","journal-title":"Molecules"},{"key":"551_CR29","doi-asserted-by":"publisher","first-page":"173634","DOI":"10.1016\/j.ejphar.2020.173634","volume":"889","author":"Y Wang","year":"2020","unstructured":"Wang, Y., & Chen, L. (2020). Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. European Journal of Pharmacology, 889, 173634. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173634","journal-title":"European Journal of Pharmacology"},{"key":"551_CR30","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1080\/07391102.2021.1871956","volume":"40","author":"PK Doharey","year":"2022","unstructured":"Doharey, P. K., Singh, V., Gedda, M. R., Sahoo, A. K., Varadwaj, P. K., & Sharma, B. (2022). In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase. Journal of Biomolecular Structure and Dynamics, 40, 5588\u20135605. https:\/\/doi.org\/10.1080\/07391102.2021.1871956","journal-title":"Journal of Biomolecular Structure and Dynamics"},{"key":"551_CR31","unstructured":"RdRp. DrugDevCovid19. Retrieved Apr 4, 2022 from http:\/\/clab.labshare.cn\/covid\/php\/database_target.php?target=RdRp&id=P0DTD1"},{"key":"551_CR32","doi-asserted-by":"publisher","first-page":"e2106379119","DOI":"10.1073\/pnas.2106379119","volume":"119","author":"NH Moeller","year":"2022","unstructured":"Moeller, N. H., Shi, K., Demir, \u00d6., Belica, C., Banerjee, S., Yin, L., Durfee, C., Amaro, R. E., & Aihara, H. (2022). Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN. Proceedings of the National Academy of Sciences USA, 119, e2106379119. https:\/\/doi.org\/10.1073\/pnas.2106379119","journal-title":"Proceedings of the National Academy of Sciences USA"},{"key":"551_CR33","unstructured":"Nsp14. DrugDevCovid19. Retrieved Apr 4, 2022 from http:\/\/clab.labshare.cn\/covid\/php\/database_target.php?target=nsp14&id=P0DTD1"},{"key":"551_CR34","doi-asserted-by":"publisher","first-page":"e1003565","DOI":"10.1371\/journal.ppat.1003565","volume":"9","author":"EC Smith","year":"2013","unstructured":"Smith, E. C., Blanc, H., Surdel, M. C., Vignuzzi, M.,\n & Denison, M. R. (2013). Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLoS Pathogens, 9, e1003565. https:\/\/doi.org\/10.1371\/journal.ppat.1003565","journal-title":"PLoS Pathogens"},{"key":"551_CR35","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.1073\/pnas.1718806115","volume":"115","author":"F Ferron","year":"2018","unstructured":"Ferron, F., Subissi, L., Silveira De Morais, A. T., Le, N. T. T., Sevajol, M., Gluais, L., Decroly, E., Vonrhein, C., Bricogne, G., Canard, B., & Imbert, I. (2018). Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proceedings of the National Academy of Sciences USA, 115, E162\u2013E171. https:\/\/doi.org\/10.1073\/pnas.1718806115","journal-title":"Proceedings of the National Academy of Sciences USA"},{"key":"551_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","volume":"584","author":"HS Hillen","year":"2020","unstructured":"Hillen, H. S., Kokic, G., Farnung, L., Dienemann, C., Tegunov, D., & Cramer, P. (2020). Structure of replicating SARS-CoV-2 polymerase. Nature, 584, 154\u2013156. https:\/\/doi.org\/10.1038\/s41586-020-2368-8","journal-title":"Nature"},{"key":"551_CR37","doi-asserted-by":"publisher","first-page":"104857","DOI":"10.1016\/j.antiviral.2020.104857","volume":"180","author":"S Jockusch","year":"2020","unstructured":"Jockusch, S., Tao, C., Li, X., Anderson, T. K., Chien, M., Kumar, S., Russo, J. J., Kirchdoerfer, R. N., & Ju, J. (2020). A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral Research, 180, 104857. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104857","journal-title":"Antiviral Research"},{"key":"551_CR38","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.3390\/molecules27072180","volume":"27","author":"A Petrou","year":"2022","unstructured":"Petrou, A., Zagaliotis, P., Theodoroula, N. F., Mystridis, G. A., Vizirianakis, I. S., Walsh, T. J., & Geronikaki, A. (2022). Thiazole\/Thiadiazole\/Benzothiazole Based Thiazolidin-4-One Derivatives as Potential Inhibitors of Main Protease of SARS-CoV-2. Molecules, 27, 2180. https:\/\/doi.org\/10.3390\/molecules27072180","journal-title":"Molecules"},{"key":"551_CR39","unstructured":"False Positive Remover. PAINS-Remover. Retrieved July 10, 2022 from https:\/\/www.cbligand.org\/PAINS\/search_struct.php"},{"key":"551_CR40","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jm901137j","volume":"53","author":"JB Baell","year":"2010","unstructured":"Baell, J. B., & Holloway, G. A. (2010). New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. Journal of Medicinal Chemistry, 53, 2719\u20132740. https:\/\/doi.org\/10.1021\/jm901137j","journal-title":"Journal of Medicinal Chemistry"}],"container-title":["Molecular Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-022-00551-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12033-022-00551-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-022-00551-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T12:12:19Z","timestamp":1713960739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12033-022-00551-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s12033-022-00551-8","relation":{},"ISSN":["1073-6085","1559-0305"],"issn-type":[{"value":"1073-6085","type":"print"},{"value":"1559-0305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"16 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors hereby declare that they totally have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this new research paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}